NCT00896532 - Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density | Biotech Hunter

Enrollment

419

Participants

Timeline

Start Date

June 3, 2009

Primary Completion Date

February 21, 2011

Study Completion Date

February 18, 2016

Conditions

Low Bone Mineral DensityPostmenopausal Osteoporosis

Interventions

DRUG

Placebo to Romosozumab

Administered by subcutaneous injection QM or Q3M.

DRUG

Alendronate

Administered orally once a week

DRUG

Teriparatide

Teriparatide 20 μg administered by subcutaneous injection once a day

DRUG

Romosozumab

Administered by subcutaneous injection

DRUG

Denosumab

Denosumab 60 mg administered by subcutaneous injection Q6M

DRUG

Placebo to Denosumab

Administered by subcutaneous injection Q6M

DRUG

Zoledronic acid

Zoledronic acid 5 mg administered intravenously